A Phase 1 interventional study of Belzutifan in End Stage Renal Disease and Renal Impairment, sponsored by Merck Sharp & Dohme LLC. Completed at 1 site in United States. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-04-06.
Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies in Kidney Failure, Chronic by Merck & Co., Inc — none open to participants now, none under way, none of them phase 3. Kidney Failure, Chronic · Merck & Co., Inc.
Among the 12 studies in Kidney Failure, Chronic by Merck & Co., Inc, this one is the 9th largest by enrollment, is one of 2 that started in 2022, is one of 10 in phase 1, and was the 6th registered.
2,112 studies on the registry are indexed under Kidney Failure, Chronic; 274 are open to participants now.
Browse Kidney Failure, Chronic studies →None of the 12 studies in Kidney Failure, Chronic by Merck & Co., Inc is open now. The open studies under Kidney Failure, Chronic, anywhere →
Of the 169 Kidney Failure, Chronic studies recruiting now, 109 (64%) set no upper age limit and 32 (19%) stop at 75 or younger; 18 take children under 18; 22 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
First in 2003; this study’s year is marked. 2 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 14 is below the median of 57 across 1,572 interventional studies indexed under Kidney Failure, Chronic.
Median enrollment 18 across the 12 interventional studies. Of the 12 that completed or were terminated, 8 (67%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Merck Sharp & Dohme LLC, one of the names counted as Merck & Co., Inc. Under that name alone:
Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.
Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 12 studies in Kidney Failure, Chronic by Merck & Co., Inc, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The primary purpose of this study is to compare the plasma pharmacokinetics (PK) of belzutifan (MK-6482) following a single oral 120 mg dose in participants with end stage renal disease (ESRD) before and after hemodialysis (HD) to each other and also to that of healthy matched control participants. This study will also evaluate the safety and tolerability of a single oral 120 mg dose of belzutifan in participants with ESRD and the extent of belzutifan removed by HD.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
For Participants With Healthy Renal Function
For Participants With end stage renal disease (ESRD)
Exclusion Criteria:
For Participants With Healthy Renal Function
Participants With ESRD
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
In period 1, participants with ESRD will receive a single, oral dose of belzutifan 120 mg on Day 1 after HD. In period 2, participants with ESRD will receive a single, oral dose of belzutifan 120 mg on Day 1 before HD. Each period is 4 days.
Drug: Belzutifan
In period 1, healthy participants will receive a single, oral dose of belzutifan 120 mg on Day 1 of a 4-day period.
Drug: Belzutifan
Three 40 mg tablets given as a single oral 120 mg dose.
Also known as: MK-6482, PT2977, WELIREG
Area Under the Plasma Concentration Time Curve of Belzutifan From Hour 0 to Infinity (AUC0-inf)
AUC0-inf was defined as the area under the concentration-time curve of belzutifan from time zero to infinity. Blood samples collected predose and at multiple timepoints postdose were used to determine AUC0-inf of belzutifan in plasma.
Time frame: Predose, and at 0.5, 1, 1.5, 2, 3, 4, 5, 6, 9, 12, 24, 36, 48, and 72 hours postdose
Area Under the Plasma Concentration Time Curve of Belzutifan From Hour 0 to 24 (AUC0-24)
AUC0-24 was defined as the area under the concentration-time curve of belzutifan from time zero to 24 hours postdose. Blood samples collected predose and at multiple timepoints postdose were used to determine AUC0-24 of belzutifan in plasma.
Time frame: Predose, and at 0.5, 1, 1.5, 2, 3, 4, 5, 6, 9, 12, and 24 hours postdose
Maximum Plasma Concentration (Cmax) of Belzutifan
Cmax is the maximum concentration of belzutifan observed in plasma. Blood samples collected predose and at multiple timepoints postdose were used to determine Cmax of belzutifan in plasma.
Time frame: Predose, and at 0.5, 1, 1.5, 2, 3, 4, 5, 6, 9, 12, 24, 36, 48, and 72 hours postdose
Time to Maximum Plasma Concentration (Tmax) of Belzutifan
Tmax is the amount of time that belzutifan is present at the maximum concentration observed in plasma. Blood samples collected predose and at multiple timepoints postdose were used to determine Tmax of belzutifan in plasma.
Time frame: Predose, and at 0.5, 1, 1.5, 2, 3, 4, 5, 6, 9, 12, 24, 36, 48, and 72 hours postdose
Apparent Terminal Half-life (t½) of Plasma Belzutifan
t1/2 is defined as the time required to divide plasma concentration of belzutifan by half. Blood samples collected predose and at multiple timepoints postdose were used to determine the apparent terminal t1/2 of belzutifan in plasma.
Time frame: Predose, and at 0.5, 1, 1.5, 2, 3, 4, 5, 6, 9, 12, 24, 36, 48, and 72 hours postdose
Dialysis Clearance of Belzutifan Based on Plasma (CLD, Plasma)
CLD, plasma is defined as a measure of the extent of belzutifan removed by HD. Blood samples collected at pre-dialysis and at multiple timepoints post-dialysis were used to measure the extent of belzutifan in plasma removal by HD.
Time frame: Pre-dialysis, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, and 4 hours post-dialysis on Day 1 of Period 2 (Study Day ~12)
Percentage of Participants Who Experienced an Adverse Event (AE)
An AE is any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the medicinal product or protocol-specified procedure. Any worsening of a preexisting condition that is temporally associated with the use of the Sponsor's product, is also an AE. The percentage of participants who experienced an AE are reported.
Time frame: Up to 32 days
Percentage of Participants Who Discontinue Study Intervention Due to an AE
An AE is any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the medicinal product or protocol-specified procedure. Any worsening of a preexisting condition that is temporally associated with the use of the Sponsor's product, is also an AE. The percentage of participants who discontinue study intervention due to an AE are reported.
Time frame: Up to 12 days
Participants with end stage renal diseases (ESRD) and healthy matched control participants were recruited at a single study site in the United States.
| Milestone | Belzutifan in Participants With ESRD | Belzutifan in Healthy Participants |
|---|---|---|
| Started | 8 | 6 |
| Completed | 8 | 6 |
| Not completed | 0 | 0 |
| Milestone | Belzutifan in Participants With ESRD | Belzutifan in Healthy Participants |
|---|---|---|
| Started | 7 | 6 |
| Completed | 7 | 6 |
| Not completed | 0 | 0 |
AUC0-inf was defined as the area under the concentration-time curve of belzutifan from time zero to infinity. Blood samples collected predose and at multiple timepoints postdose were used to determine AUC0-inf of belzutifan in plasma.
| ng•hr/mL | Belzutifan in Participants With ESRD Before HD (Period 2) | Belzutifan in ESRD After HD (Period 1) | Belzutifan in Healthy Participants |
|---|---|---|---|
| Area Under the Plasma Concentration Time Curve of Belzutifan From Hour 0 to Infinity (AUC0-inf) | 17100 ± 91.3 | 21100 ± 91.3 | 18500 ± 41.4 |
AUC0-24 was defined as the area under the concentration-time curve of belzutifan from time zero to 24 hours postdose. Blood samples collected predose and at multiple timepoints postdose were used to determine AUC0-24 of belzutifan in plasma.
| ng•hr/mL | Belzutifan in Participants With ESRD Before HD (Period 2) | Belzutifan in Participants With ESRD After HD (Period 1) | Belzutifan in Healthy Participants |
|---|---|---|---|
| Area Under the Plasma Concentration Time Curve of Belzutifan From Hour 0 to 24 (AUC0-24) | 10700 ± 50.5 | 12300 ± 50.7 | 13200 ± 30.7 |
Cmax is the maximum concentration of belzutifan observed in plasma. Blood samples collected predose and at multiple timepoints postdose were used to determine Cmax of belzutifan in plasma.
| ng/mL | Belzutifan in Participants With ESRD Before HD (Period 2) | Belzutifan in Participants With ESRD After HD (Period 1) | Belzutifan in Healthy Participants |
|---|---|---|---|
| Maximum Plasma Concentration (Cmax) of Belzutifan | 1110 ± 44.0 | 907 ± 46.7 | 1300 ± 26.1 |
Tmax is the amount of time that belzutifan is present at the maximum concentration observed in plasma. Blood samples collected predose and at multiple timepoints postdose were used to determine Tmax of belzutifan in plasma.
| hour | Belzutifan in Participants With ESRD Before HD (Period 2) | Belzutifan in Participants With ESRD After HD (Period 1) | Belzutifan in Healthy Participants |
|---|---|---|---|
| Time to Maximum Plasma Concentration (Tmax) of Belzutifan | 2.00 (1.00 to 3.00) | 4.00 (1.50 to 9.00) | 1.00 (0.50 to 3.00) |
t1/2 is defined as the time required to divide plasma concentration of belzutifan by half. Blood samples collected predose and at multiple timepoints postdose were used to determine the apparent terminal t1/2 of belzutifan in plasma.
| hour | Belzutifan in Participants With ESRD Before HD (Period 2) | Belzutifan in Participants With ESRD After HD (Period 1) | Belzutifan in Healthy Participants |
|---|---|---|---|
| Apparent Terminal Half-life (t½) of Plasma Belzutifan | 15.1 ± 68.1 | 17.1 ± 57.6 | 13.9 ± 20.9 |
CLD, plasma is defined as a measure of the extent of belzutifan removed by HD. Blood samples collected at pre-dialysis and at multiple timepoints post-dialysis were used to measure the extent of belzutifan in plasma removal by HD.
| mL/min | Belzutifan in Participants With ESRD Before HD (Period 2) |
|---|---|
| Dialysis Clearance of Belzutifan Based on Plasma (CLD, Plasma) | 78.4 ± 53.5 |
An AE is any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the medicinal product or protocol-specified procedure. Any worsening of a preexisting condition that is temporally associated with the use of the Sponsor's product, is also an AE. The percentage of participants who experienced an AE are reported.
| Percentage of Participants | Belzutifan in Participants With ESRD Before HD (Period 2) | Belzutifan in Participants With ESRD After HD (Period 1) | Belzutifan in Healthy Participants |
|---|---|---|---|
| Percentage of Participants Who Experienced an Adverse Event (AE) | 14.3 | 0.0 | 16.7 |
An AE is any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the medicinal product or protocol-specified procedure. Any worsening of a preexisting condition that is temporally associated with the use of the Sponsor's product, is also an AE. The percentage of participants who discontinue study intervention due to an AE are reported.
| Percentage of Participants | Belzutifan in Participants With ESRD Before HD (Period 2) | Belzutifan in Participants With ESRD After HD (Period 1) | Belzutifan in Healthy Participants |
|---|---|---|---|
| Percentage of Participants Who Discontinue Study Intervention Due to an AE | 0.0 | 0.0 | 0.0 |
Collected over Up to 32 days.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Belzutifan in Participants With ESRD Before HD (Period 2) | 0/7 (0%) | 1/7 (14.3%) | 0/7 (0%) |
| Belzutifan in Participants With ESRD After HD (Period 2) | 0/8 (0%) | 0/8 (0%) | 0/8 (0%) |
| Belzutifan in Healthy Participants | 0/6 (0%) | 0/6 (0%) | 1/6 (16.7%) |
| Event | Belzutifan in Participants With ESRD Before HD (Period 2) | Belzutifan in Participants With ESRD After HD (Period 2) | Belzutifan in Healthy Participants |
|---|---|---|---|
| BacteraemiaInfections and infestations | 1/7 | 0/8 | 0/6 |
| Event | Belzutifan in Participants With ESRD Before HD (Period 2) | Belzutifan in Participants With ESRD After HD (Period 2) | Belzutifan in Healthy Participants |
|---|---|---|---|
| HeadacheNervous system disorders | 0/7 | 0/8 | 1/6 |
| Age, Continuous(Years) | Belzutifan in Participants With ESRD | Belzutifan in Healthy Participants | Total |
|---|---|---|---|
| Mean | 57.3 ± 8.48 | 55.5 ± 7.42 | 56.5 ± 7.79 |
| Sex: Female, Male(Participants) | Belzutifan in Participants With ESRD | Belzutifan in Healthy Participants | Total |
|---|---|---|---|
| Female | 8 | 6 | 14 |
| Male | 0 | 0 | 0 |
| Ethnicity (NIH/OMB)(Participants) | Belzutifan in Participants With ESRD | Belzutifan in Healthy Participants | Total |
|---|---|---|---|
| Hispanic or Latino | 2 | 1 | 3 |
| Not Hispanic or Latino | 6 | 5 | 11 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Belzutifan in Participants With ESRD | Belzutifan in Healthy Participants | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 7 | 2 | 9 |
| White | 0 | 4 | 4 |
| More than one race | 1 | 0 | 1 |
| Unknown or Not Reported | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf
Data sharing details ↗ · engagezone.msd.com
Ran from Jul 2022 to primary completion in Apr 2024, 20 months.
Results were first posted in Apr 2025, 1 year after primary completion.
Of 46 industry-sponsored phase 1 interventional studies under Kidney Failure, Chronic, half reached primary completion within 7 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 16. This study's 20 months is above that.
Counting every sponsor, half of 67 studies reached it within 12 months; a quarter within 5 and three quarters within 27.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Belzutifan